PSA bouncing after short term androgen deprivation and 3D-conformal radiotherapy for localized prostate adenocarcinoma and the relationship with the kinetics of testosterone
- PMID: 15967250
- DOI: 10.1016/j.eururo.2005.04.007
PSA bouncing after short term androgen deprivation and 3D-conformal radiotherapy for localized prostate adenocarcinoma and the relationship with the kinetics of testosterone
Abstract
Objectives: To assess the factors effecting PSA bounce and to identify any possible relationship with biochemical control after 3-D conformal radiotherapy (3D-CRT) and total androgen deprivation (TAD) for prostate cancer by evaluating four previously described PSA bounce definitions.
Methods: Between January 1998 and January 2001, 83 consecutive patients with clinically localized prostate cancer were treated by 3D-CRT with neoadjuvant 3 months and/or 6 months adjuvant TAD. All patients had a pretreatment PSA level, at least eight post-external beam radiotherapy (EBRT) PSA and testosterone levels and minimum two years of follow-up. Total radiotherapy dose was 73.6 Gy at ICRU reference point. Four previous definitions of PSA bounce were used: Critz definition (>or=0.1 ng/mL), Cavanagh definition (>or=0.2 ng/mL), Hanlon definition (>or=0.4 ng/mL) and Rosser definition (>or=0.5 ng/mL) according to original methodology performed to report PSA bounce. Biochemical failure was defined in accordance with the ASTRO consensus guidelines.
Results: The median follow-up time was 40 months. PSA bounce was recorded as follows: Critz definition, 33 patients (40%); Cavanagh definition, 21 patients (25%); Hanlon definition, 11 patients (13%); and Rosser definition, 7 patients (8%). In multivariate analysis, pre-EBRT PSA level and the duration of TAD for Critz definition; age, pre-EBRT PSA and the duration of TAD for Cavanagh definition; age and duration of TAD for Hanlon definition; age and pre-biopsy PSA for Rosser definition were significant independent prognostic factors determining PSA bounce. A significant increase of mean testosterone level in bouncers was detected at the 6th-9th and 18th-21st months. PSA bounce did not predict for PSA failure in multivariate analysis.
Conclusions: We observed no correlation between biochemical failure and PSA bounce. The longer duration of TAD and older age were found to be inversely proportional with PSA bouncing in this cohort. Notably, recovery of testosterone might cause PSA bouncing.
Similar articles
-
Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):415-9. doi: 10.1016/j.ijrobp.2004.05.018. Int J Radiat Oncol Biol Phys. 2005. PMID: 15667961
-
Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.Cancer. 2005 Jun 15;103(12):2499-506. doi: 10.1002/cncr.21077. Cancer. 2005. PMID: 15852361
-
[PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure].Cancer Radiother. 2007 May;11(3):105-10. doi: 10.1016/j.canrad.2006.10.005. Epub 2006 Dec 8. Cancer Radiother. 2007. PMID: 17158082 French.
-
High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results.Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1306-16. doi: 10.1016/j.ijrobp.2004.08.014. Int J Radiat Oncol Biol Phys. 2005. PMID: 15817332 Review.
-
The role of external radiotherapy in patients treated with permanent prostate brachytherapy.Prostate Cancer Prostatic Dis. 2002;5(1):47-53. doi: 10.1038/sj.pcan.4500552. Prostate Cancer Prostatic Dis. 2002. PMID: 15195130 Review.
Cited by
-
PSA bouncing after brachytherapy HDR and external beam radiation therapy: a study of 121 patients with minimum 5-years follow-up.J Contemp Brachytherapy. 2009 Jun;1(2):92-96. Epub 2009 Jul 17. J Contemp Brachytherapy. 2009. PMID: 27795718 Free PMC article.
-
Prostate-specific antigen bounce predicts for a favorable prognosis following brachytherapy: a meta-analysis.J Contemp Brachytherapy. 2013 Dec;5(4):210-4. doi: 10.5114/jcb.2013.38875. Epub 2013 Nov 14. J Contemp Brachytherapy. 2013. PMID: 24474969 Free PMC article.
-
Preliminary results of bicalutamide monotherapy on biochemical failure of localized prostate cancer.J Natl Med Assoc. 2006 Jul;98(7):1058-61. J Natl Med Assoc. 2006. PMID: 16895273 Free PMC article.
-
Clinical implications of a prostate-specific antigen bounce after radiation therapy for prostate cancer.Int J Clin Oncol. 2015 Jun;20(3):598-604. doi: 10.1007/s10147-014-0745-8. Epub 2014 Sep 6. Int J Clin Oncol. 2015. PMID: 25193155
-
Long-term prognostic significance of rising PSA levels following radiotherapy for localized prostate cancer - focus on overall survival.Radiat Oncol. 2017 Jun 14;12(1):98. doi: 10.1186/s13014-017-0837-5. Radiat Oncol. 2017. PMID: 28615058 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous